文章：

Blinatumomab与Inotuzumab Ozogamicin序贯治疗复发/难治性急性淋巴细胞白血病：一项真实世界Campus All研究

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

原文发布日期：19 September 2023

DOI: 10.3390/cancers15184623

类型: Article

开放获取: 是

英文摘要：

Background: Blinatumomab (Blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, little is known about the outcome after recurrence and re-treatment with immunotherapy. Methods: We describe 71 R/R B-ALL patients treated for different relapses with Blina and InO. Blina was the first treatment in 57 patients and InO in 14. Twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD−); after InO, a CR was achieved in 47 patients (82%, 34 MRD−). In the InO/Blina group, after InO, 13 cases (93%) reached a CR (6 MRD−); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD−). Twenty-six patients proceeded to allo-HSCT. In the Blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after Blina was 7.4 months (11.6 vs. 2.7 months in MRD− vs. MRD+,p= 0.03) and after InO, 5.4 months. In the InO/Blina group, the median OS was 9.4 months; the median DFS after InO was 5.1 months and 1.5 months after Blina (8.7 vs. 2.5 months in MRD− vs. MRD+,p= 0.02). With a median follow-up of 16.5 months from the start of immunotherapy, 24 patients (34%) are alive and 16 (22%) are alive in CR. Conclusion: In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.

摘要翻译： 

背景：贝林妥欧单抗（Blina）与奥加伊妥珠单抗（InO）的应用改善了复发/难治性B淋巴细胞白血病（R/R B-ALL）的临床结局，但关于免疫治疗后复发及再次治疗的疗效数据仍较为有限。方法：本研究纳入71例接受Blina与InO序贯治疗不同阶段复发的R/R B-ALL患者，其中57例首次治疗采用Blina，14例首次治疗采用InO。27例患者既往曾接受异基因造血干细胞移植（allo-HSCT）。结果：在Blina/InO序贯组中，Blina治疗后36例（63%）获得完全缓解（CR），其中42%达到微小残留病阴性（MRD−）；InO治疗后47例（82%）获得CR（其中34例MRD−）。在InO/Blina序贯组中，InO治疗后13例（93%）获得CR（其中6例MRD−）；Blina治疗后6例（43%）再次获得CR（其中3例MRD−）。共有26例患者后续接受了allo-HSCT。Blina/InO组中位总生存期（OS）为19个月；Blina治疗后无病生存期（DFS）为7.4个月（MRD−与MRD+患者分别为11.6个月 vs. 2.7个月，p=0.03），InO治疗后DFS为5.4个月。InO/Blina组中位OS为9.4个月；InO治疗后中位DFS为5.1个月，Blina治疗后为1.5个月（MRD−与MRD+患者分别为8.7个月 vs. 2.5个月，p=0.02）。中位随访16.5个月（自免疫治疗起始计算），24例（34%）患者存活，其中16例（22%）维持CR状态。结论：在本系列R/R B-ALL患者中，Blina与InO序贯治疗对后续复发仍显示出明确的疗效，体现在MRD应答率、OS与DFS的改善，并可作为allo-HSCT的有效桥接治疗手段。

原文链接：

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study